AVN to compete w/ ABGX -- Stock Picks

[ Show ]

Support VoyForums

[ Shrink ]

VoyForums Announcement: Programming and providing support for this service has been a labor of love since 1997. We are one of the few services online who values our users' privacy, and have never sold your information. We have even fought hard to defend your privacy in legal cases; however, we've done it with almost no financial support -- paying out of pocket to continue providing the service. Due to the issues imposed on us by advertisers, we also stopped hosting most ads on the forums many years ago. We hope you appreciate our efforts.

Show your support by donating any amount. (Note: We are still technically a for-profit company, so your contribution is not tax-deductible.) PayPal Acct: Feedback:

Donate to VoyForums (PayPal):

[ Login ] [ Contact Forum Admin ] [ Main index ] [ Post a new message ] [ Search | Check update time | Archives: 1, 2 ]

[ Next Thread | Previous Thread | Next Message | Previous Message ]

Date Posted: 06:23:22 07/25/00 Tue
Author: AVN to compete w/ ABGX
Subject: AVN to compete w/ ABGX

Rituxin (from IDPH)
was the first FDA approved drug for cancer (in the US) utilizing monoclonal antibodies. This could have important significance to AVN if they developed it using "monomouse" technology. AVN who owns 100% of the patent equally with IDPH has stated that they have a verbal agreement with IDPH to commercialize "monomice" technology. If brought to the market, "monomouse" technology may compete with ABGX's "xenomouse" and MEDX's "humabmouse". Both ABGX and MEDX became high flying stocks this year based on the mouse technology. AVN, which still sells for less than $4 per share, feels that their technology is superior to that of ABGX and MEDX. AVN has stated that they will announce plans to commercialize "monomouse" technology within 30-60 days or
sooner. AVN has also recently been approved for the first over the counter herpes cream using n-docosanol. The product
will be marketed by SBH upon final labeling approval. In addition, AVN has the exciting IgE technology in the pipeline which may help bring relief someday to millions of allergy sufferers. The possibility of developing IgE and monoclonal antibodies could make a perfect combination. This puts AVN in company with Genentech (DNA) who have similiar technology using humanized antibodies.

http://biz.yahoo.com/p/a/avn.html

http://www.avanir.com/

[ Next Thread | Previous Thread | Next Message | Previous Message ]